Abstract | BACKGROUND & AIMS: METHODS: We studied data from 219 patients with β- thalassemia, collected from histologic analyses of biopsy samples taken at baseline and after at least 3 years of treatment with deferasirox. Treatment response was assessed from liver iron concentrations at baseline and the end of the study. Liver fibrosis, necroinflammation, and markers of iron overload and liver enzymes were recorded. Patients were also assessed, by serologic analysis at baseline, for hepatitis C virus infection. RESULTS: By the end of the study, stability of Ishak fibrosis staging scores (change of -1, 0, or +1) or improvements (change of ≤-2) were observed in 82.6% of patients; Ishak necroinflammatory scores improved by a mean value of -1.3 (P<.001). Improvements in fibrosis stage and necroinflammation were independent of hepatitis C virus exposure or reduction in liver iron concentration defined by the response criteria. Absolute changes in concentrations of liver iron by the end of the study did not correlate with improved Ishak fibrosis or necroinflammatory scores. CONCLUSIONS:
|
Authors | Yves Deugnier, Bruno Turlin, Martine Ropert, M Domenica Cappellini, John B Porter, Vanessa Giannone, Yiyun Zhang, Louis Griffel, Pierre Brissot |
Journal | Gastroenterology
(Gastroenterology)
Vol. 141
Issue 4
Pg. 1202-11, 1211.e1-3
(Oct 2011)
ISSN: 1528-0012 [Electronic] United States |
PMID | 21741344
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Benzoates
- Biomarkers
- Iron Chelating Agents
- Triazoles
- Ferritins
- Iron
- Alanine Transaminase
- Deferasirox
|
Topics |
- Adolescent
- Adult
- Alanine Transaminase
(blood)
- Benzoates
(therapeutic use)
- Biomarkers
(blood)
- Biopsy
- Child
- Child, Preschool
- Cross-Over Studies
- Deferasirox
- Female
- Ferritins
(blood)
- Hepatitis C
(pathology)
- Humans
- Iron
(metabolism)
- Iron Chelating Agents
(therapeutic use)
- Liver
(drug effects, metabolism, pathology)
- Liver Cirrhosis
(blood, drug therapy, etiology, pathology)
- Male
- Middle Aged
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Triazoles
(therapeutic use)
- Young Adult
- beta-Thalassemia
(blood, complications, drug therapy, pathology)
|